Cargando…

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

During these last years, there have been an increased number of new drugs for non-small cell lung cancer (NSCLC), with a growing financial effect on patients and society. The purpose of this article was to review the economics of first-line and maintenance NSCLC treatments. We reviewed economic anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chouaïd, Christos, Crequit, Perinne, Borget, Isabelle, Vergnenegre, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271788/ https://www.ncbi.nlm.nih.gov/pubmed/25548525 http://dx.doi.org/10.2147/CEOR.S43328

Ejemplares similares

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
por: Vergnenègre, A, et al.
Publicado: (2013)

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
por: Vergnenègre, Alain, et al.
Publicado: (2012)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
por: Christos, Chouaid, et al.
Publicado: (2012)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
por: Walleser, Silke, et al.
Publicado: (2012)

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
por: Taipale, Kaisa, et al.
Publicado: (2017)

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined
por: Chouaïd, Christos, et al.
Publicado: (2020)

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers
por: Dusselier, Matthieu, et al.
Publicado: (2019)

Economics of the clinical management of lung cancer in France: an analysis using a Markov model
por: Chouaïd, C, et al.
Publicado: (2004)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France
por: Atsou, Kokuvi, et al.
Publicado: (2016)

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2021)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor
por: Créquit, Perrine, et al.
Publicado: (2016)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer
por: Lerouge, Delphine, et al.
Publicado: (2014)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
por: Vergnenègre, Alain, et al.
Publicado: (2019)

Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004
por: Valin, Nadia, et al.
Publicado: (2010)

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends
por: Chouaid, Christos, et al.
Publicado: (2016)

Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis
por: Créquit, Perrine, et al.
Publicado: (2017)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)
por: LeCaer, H, et al.
Publicado: (2011)

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
por: Nemunaitis, John, et al.
Publicado: (2015)

Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study
por: Heraudet, Luc, et al.
Publicado: (2022)

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
por: Gendarme, Sébastien, et al.
Publicado: (2022)

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation
por: Han, Kelong, et al.
Publicado: (2016)

Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations
por: Tan, Pui San, et al.
Publicado: (2017)

Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
por: Jun, Ni, et al.
Publicado: (2020)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
por: Bylicki, Olivier, et al.
Publicado: (2018)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
por: Bylicki, Olivier, et al.
Publicado: (2020)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty
por: Martelli, Nicolas, et al.
Publicado: (2015)

Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
por: Prabhash, Kumar
Publicado: (2019)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi, Shipra, et al.
Publicado: (2015)

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer
por: Yang, Szu‐Chun, et al.
Publicado: (2023)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
por: Vergnenegre, Alain, et al.
Publicado: (2019)

Systematic analysis of design and stratification for phase III trials in first‐line advanced non‐small cell lung cancer
por: Komiya, Takefumi, et al.
Publicado: (2015)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5u4r0v283s2115c45ri5kelqu3